Literature DB >> 16091946

Validated HPLC-MS-MS method for determination of azithromycin in human plasma.

B Barrett1, V Borek-Dohalský, P Fejt, S Vaingátová, J Huclová, B Nemec, I Jelínek.   

Abstract

A validated, highly sensitive, and selective HPLC method with MS-MS detection has been developed for quantitative determination of azithromycin (AZI) in human Na2EDTA plasma. Roxithromycin (ROX) was used as internal standard. Human plasma containing AZI and internal standard was ultrafiltered through Centrifree Micropartition devices and the concentration of AZI was determined by isocratic HPLC-MS-MS. Multiple reaction monitoring mode (MRM) was used for MS-MS detection. The calibration plot was linear in the concentration range 2.55-551.43 ng mL(-1). Inter-day and Intra-day precision and accuracy of the proposed method were characterized by R.S.D and percentage deviation, respectively; both were less than 8%. Limit of quantification was 2.55 ng mL(-1). The proposed method was used to determine the pharmacokinetic profile of AZI (250-mg tablets).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091946     DOI: 10.1007/s00216-005-0018-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

1.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

2.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  Fluorescence determination of azithromycin in pharmaceutical formulations by using the synchronous scanning approach after its acid derivatization.

Authors:  Vanessa G K Almeida; Victor S M Braga; Wagner F Pacheco; Ricardo J Cassella
Journal:  J Fluoresc       Date:  2012-08-29       Impact factor: 2.217

4.  Bioequivalence of 2 azithromycin capsule formulations: a randomized, single-dose, open-label, 2-period crossover study in healthy male pakistani volunteers.

Authors:  Zafar Iqbal; Muhammad Imran Khan; Abbas Khan; Abad Khan; Yasar Shah; Lateef Ahmad
Journal:  Curr Ther Res Clin Exp       Date:  2011-06

5.  A simple, high-throughput and validated LC-MS/MS method for the determination of azithromycin in human plasma and its application to a clinical pharmacokinetic study.

Authors:  Yuning Zhang; Veenu Bala; Yashpal S Chhonker; Wafaa N Aldhafiri; Lucy N John; Catherine M Bjerum; Christopher L King; Oriol Mitja; Michael Marks; Daryl J Murry
Journal:  Biomed Chromatogr       Date:  2022-07-19       Impact factor: 1.911

6.  The pharmacokinetic-pharmacodynamic model of azithromycin for lipopolysaccharide-induced depressive-like behavior in mice.

Authors:  Kun Hao; Qu Qi; Haiping Hao; Guangji Wang; Yuancheng Chen; Yan Liang; Lin Xie
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.